Recent advances in intestinal lymphomas

Histopathology

Volumn 66, Issue 1, 2015, Pages 112-136

  Foukas, Periklis G ^a,b   de Leval, Laurence ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Diagnosis; Indolent lymphoproliferations; Intestines; Lymphomas; Pathology

Indexed keywords

BURKITT LYMPHOMA; CLINICAL FEATURE; FOLLICULAR LYMPHOMA; HUMAN; IMMUNOPROLIFERATIVE SMALL INTESTINAL DISEASE; INTESTINE LYMPHOMA; LYMPHOCYTE PROLIFERATION; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; PRIORITY JOURNAL; REVIEW; TUMOR CLASSIFICATION; INTESTINE TUMOR; LYMPHOMA; PATHOLOGY;

HUMAN HERPESVIRUS 4;

HUMANS; INTESTINAL NEOPLASMS; LYMPHOMA;

EID: 84920998234     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12596     Document Type: Review

References (105)

1. Howell JM, Auer-Grzesiak I, Zhang J, Andrews CN, Stewart D, Urbanski SJ. Increasing incidence rates, distribution and histological characteristics of primary gastrointestinal non-Hodgkin lymphoma in a North American population. Can. J. Gastroenterol. 2012; 26; 452-456.
2. Andrews CN, John Gill M, Urbanski SJ, Stewart D, Perini R, Beck P. Changing epidemiology and risk factors for gastrointestinal non-Hodgkin's lymphoma in a North American population: population-based study. Am. J. Gastroenterol. 2008; 103; 1762-1769.
3. Koch P, del Valle F, Berdel WE et al. Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J. Clin. Oncol. 2001; 19; 3861-3873.
4. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. Lyon: IARC Press, 2010.
5. Kohno S, Ohshima K, Yoneda S, Kodama T, Shirakusa T, Kikuchi M. Clinicopathological analysis of 143 primary malignant lymphomas in the small and large intestines based on the new WHO classification. Histopathology 2003; 43; 135-143.
6. Kim SJ, Choi CW, Mun YC et al. Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL). BMC Cancer 2011; 11; 321.
7. Grogg KL, Miller RF, Dogan A. HIV infection and lymphoma. J. Clin. Pathol. 2007; 60; 1365-1372.
8. Aigner F, Boeckle E, Albright J et al. Malignancies of the colorectum and anus in solid organ recipients. Transpl. Int. 2007; 20; 497-504.
9. Holubar SD, Dozois EJ, Loftus EV Jr et al. Primary intestinal lymphoma in patients with inflammatory bowel disease: a descriptive series from the prebiologic therapy era. Inflamm. Bowel Dis. 2011; 17; 1557-1563.
10. Chiorean MV, Pokhrel B, Adabala J, Helper DJ, Johnson CS, Juliar B. Incidence and risk factors for lymphoma in a single-center inflammatory bowel disease population. Dig. Dis. Sci. 2011; 56; 1489-1495.
11. Oh SY, Kwon HC, Kim WS et al. Intestinal marginal zone B-cell lymphoma of MALT type: clinical manifestation and outcome of a rare disease. Eur. J. Haematol. 2007; 79; 287-291.
12. Argyropoulos T, Foukas P, Kefala M et al. Simultaneous occurrence of colonic adenocarcinoma and MALT lymphoma: a series of three cases. World J. Gastrointest. Oncol. 2012; 4; 89-93.
13. Isaacson PG, Du MQ. Gastrointestinal lymphoma: where morphology meets molecular biology. J. Pathol. 2005; 205; 255-274.
14. Sinn DH, Kim YH, Lee EJ, Ko YH, Kim KM. Methylation and API2/MALT1 fusion in colorectal extranodal marginal zone lymphoma. Mod. Pathol. 2009; 22; 314-320.
15. Streubel B, Seitz G, Stolte M, Birner P, Chott A, Raderer M. MALT lymphoma associated genetic aberrations occur at different frequencies in primary and secondary intestinal MALT lymphomas. Gut 2006; 55; 1581-1585.
16. Zhang S, Wei M, Liang Q et al. The t(14;18)(q32;q21)/IGH-MALT1 translocation in gastrointestinal extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). Histopathology 2014; 64; 791-798.
17. Yoshida N, Nomura K, Wakabayashi N et al. Cytogenetic and clinicopathological characterization by fluorescence in situ hybridization on paraffin-embedded tissue sections of twenty-six cases with malignant lymphoma of small intestine. Scand. J. Gastroenterol. 2006; 41; 212-222.
18. Sakugawa ST, Yoshino T, Nakamura S et al. API2-MALT1 fusion gene in colorectal lymphoma. Mod. Pathol. 2003; 16; 1232-1241.
19. Attygalle AD, Liu H, Shirali S et al. Atypical marginal zone hyperplasia of mucosa-associated lymphoid tissue: a reactive condition of childhood showing immunoglobulin lambda light-chain restriction. Blood 2004; 104; 3343-3348.
20. de Boer JP, Hiddink RF, Raderer M et al. Dissemination patterns in non-gastric MALT lymphoma. Haematologica 2008; 93; 201-206.
21. Niino D, Yamamoto K, Tsuruta O et al. Regression of rectal mucosa-associated lymphoid tissue (MALT) lymphoma after antibiotic treatments. Pathol. Int. 2010; 60; 438-442.
22. Swerdlow SH, Campo E, Harris NL et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2008.
23. Al-Saleem T, Al-Mondhiry H. Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms. Blood 2005; 105; 2274-2280.
24. Lecuit M, Abachin E, Martin A et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N. Engl. J. Med. 2004; 350; 239-248.
25. Coeuret S, de La Blanchardiere A, Saguet-Rysanek V et al. Campylobacter coli cultured from the stools of a patient with immunoproliferative small intestinal disease. Clin. Microbiol. Infect. 2014; 20; 908-911.
26. Misdraji J, Harris NL, Hasserjian RP, Lauwers GY, Ferry JA. Primary follicular lymphoma of the gastrointestinal tract. Am. J. Surg. Pathol. 2011; 35; 1255-1263.
27. Norimura D, Isomoto H, Imaizumi Y et al. Case series of duodenal follicular lymphoma, observed by magnified endoscopy with narrow-band imaging. Gastrointest. Endosc. 2011; 74; 428-434.
28. Schmatz AI, Streubel B, Kretschmer-Chott E et al. Primary follicular lymphoma of the duodenum is a distinct mucosal/submucosal variant of follicular lymphoma: a retrospective study of 63 cases. J. Clin. Oncol. 2011; 29; 1445-1451.
29. Takata K, Sato Y, Nakamura N et al. Duodenal follicular lymphoma lacks AID but expresses BACH2 and has memory B-cell characteristics. Mod. Pathol. 2013; 26; 22-31.
30. Takata K, Okada H, Ohmiya N et al. Primary gastrointestinal follicular lymphoma involving the duodenal second portion is a distinct entity: a multicenter, retrospective analysis in Japan. Cancer Sci. 2011; 102; 1532-1536.
31. Takata K, Sato Y, Nakamura N et al. Duodenal and nodal follicular lymphomas are distinct: the former lacks activation-induced cytidine deaminase and follicular dendritic cells despite ongoing somatic hypermutations. Mod. Pathol. 2009; 22; 940-949.
32. Mamessier E, Song JY, Eberle FC et al. Early lesions of follicular lymphoma: a genetic perspective. Haematologica 2014; 99; 481-488.
33. Sato Y, Ichimura K, Tanaka T et al. Duodenal follicular lymphomas share common characteristics with mucosa-associated lymphoid tissue lymphomas. J. Clin. Pathol. 2008; 61; 377-381.
34. Takata K, Tanino M, Ennishi D et al. Duodenal follicular lymphoma: comprehensive gene expression analysis with insights into pathogenesis. Cancer Sci. 2014; 105; 608-615.
35. Bende RJ, Smit LA, Bossenbroek JG et al. Primary follicular lymphoma of the small intestine: alpha4beta7 expression and immunoglobulin configuration suggest an origin from local antigen-experienced B cells. Am. J. Pathol. 2003; 162; 105-113.
36. Wu W, Doan N, Said J, Karunasiri D, Pullarkat ST. Strong expression of chemokine receptor CCR9 in diffuse large B-cell lymphoma and follicular lymphoma strongly correlates with gastrointestinal involvement. Hum. Pathol. 2014; 45; 1451-1458.
37. Romaguera JE, Medeiros LJ, Hagemeister FB et al. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 2003; 97; 586-591.
38. Kodama T, Ohshima K, Nomura K et al. Lymphomatous polyposis of the gastrointestinal tract, including mantle cell lymphoma, follicular lymphoma and mucosa-associated lymphoid tissue lymphoma. Histopathology 2005; 47; 467-478.
39. Geissmann F, Ruskone-Fourmestraux A, Hermine O et al. Homing receptor alpha4beta7 integrin expression predicts digestive tract involvement in mantle cell lymphoma. Am. J. Pathol. 1998; 153; 1701-1705.
40. Salaverria I, Royo C, Carvajal-Cuenca A et al. CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma. Blood 2013; 121; 1394-1402.
41. Soldini D, Valera A, Sole C et al. Assessment of SOX11 expression in routine lymphoma tissue sections: characterization of new monoclonal antibodies for diagnosis of mantle cell lymphoma. Am. J. Surg. Pathol. 2014; 38; 86-93.
42. Katzenberger T, Petzoldt C, Holler S et al. The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood 2006; 107; 3407.
43. Garcia M, Romaguera JE, Inamdar KV, Rassidakis GZ, Medeiros LJ. Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine. Cancer 2009; 115; 1041-1048.
44. Schmitz R, Ceribelli M, Pittaluga S, Wright G, Staudt LM. Oncogenic mechanisms in Burkitt lymphoma. Cold Spring Harb. Perspect Med. 2014; 4: a014282.
45. Ferry JA. Extranodal lymphomas. Philadelphia, PA: Elsevier, Saunders, 2011.
46. Green TM, Nielsen O, de Stricker K, Xu-Monette ZY, Young KH, Moller MB. High levels of nuclear MYC protein predict the presence of MYC rearrangement in diffuse large B-cell lymphoma. Am. J. Surg. Pathol. 2012; 36; 612-619.
47. Richter J, Schlesner M, Hoffmann S et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat. Genet. 2012; 44; 1316-1320.
48. Schmitz R, Young RM, Ceribelli M et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012; 490; 116-120.
49. Cattoretti G. MYC expression and distribution in normal mature lymphoid cells. J. Pathol. 2013; 229; 430-440.
50. Nakamura S, Matsumoto T, Iida M, Yao T, Tsuneyoshi M. Primary gastrointestinal lymphoma in Japan: a clinicopathologic analysis of 455 patients with special reference to its time trends. Cancer 2003; 97; 2462-2473.
51. Gou HF, Zang J, Jiang M, Yang Y, Cao D, Chen XC. Clinical prognostic analysis of 116 patients with primary intestinal non-Hodgkin lymphoma. Med. Oncol. 2012; 29; 227-234.
52. Wong MT, Eu KW. Primary colorectal lymphomas. Colorectal Dis. 2006; 8; 586-591.
53. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011; 117; 5019-5032.
54. Kim SJ, Kang HJ, Kim JS et al. Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone. Blood 2011; 117; 1958-1965.
55. Chuang SS, Ye H, Yang SF et al. Perforation predicts poor prognosis in patients with primary intestinal diffuse large B-cell lymphoma. Histopathology 2008; 53; 432-440.
56. Connor J, Ashton-Key M. Gastric and intestinal diffuse large B-cell lymphomas are clinically and immunophenotypically different. An immunohistochemical and clinical study. Histopathology 2007; 51; 697-703.
57. Choi WW, Weisenburger DD, Greiner TC et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin. Cancer Res. 2009; 15; 5494-5502.
58. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103; 275-282.
59. Mitchell KA, Finn WG, Owens SR. Differences in germinal centre and non-germinal center phenotype in gastric and intestinal diffuse large B-cell lymphomas. Leuk. Lymphoma 2008; 49; 1717-1723.
60. Hummel M, Bentink S, Berger H et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N. Engl. J. Med. 2006; 354; 2419-2430.
61. Farris AB, Lauwers GY, Ferry JA, Zukerberg LR. The rectal tonsil: a reactive lymphoid proliferation that may mimic lymphoma. Am. J. Surg. Pathol. 2008; 32; 1075-1079.
62. Tavora F, Gonzalez-Cuyar LF, Sun CC, Burke A, Zhao XF. Extra-oral plasmablastic lymphoma: report of a case and review of literature. Hum. Pathol. 2006; 37; 1233-1236.
63. Valera A, Balague O, Colomo L et al. IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am. J. Surg. Pathol. 2010; 34; 1686-1694.
64. Wang HW, Yang W, Sun JZ, Lu JY, Li M, Sun L. Plasmablastic lymphoma of the small intestine: case report and literature review. World J. Gastroenterol. 2012; 18; 6677-6681.
65. Taddesse-Heath L, Meloni-Ehrig A, Scheerle J, Kelly JC, Jaffe ES. Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features. Mod. Pathol. 2010; 23; 991-999.
66. Pan ZG, Zhang QY, Lu ZB et al. Extracavitary KSHV-associated large B-Cell lymphoma: a distinct entity or a subtype of primary effusion lymphoma? Study of 9 cases and review of an additional 43 cases Am J Surg Pathol 2012; 36; 1129-1140.
67. Kim Y, Leventaki V, Bhaijee F, Jackson CC, Medeiros LJ, Vega F. Extracavitary/solid variant of primary effusion lymphoma. Ann. Diagn. Pathol. 2012; 16; 441-446.
68. Ok CY, Papathomas TG, Medeiros LJ, Young KH. EBV-positive diffuse large B-cell lymphoma of the elderly. Blood 2013; 122; 328-340.
69. Oyama T, Yamamoto K, Asano N et al. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin. Cancer Res. 2007; 13; 5124-5132.
70. Delabie J, Holte H, Vose JM et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. Blood 2011; 118; 148-155.
71. Malamut G, Chandesris O, Verkarre V et al. Enteropathy associated T cell lymphoma in celiac disease: a large retrospective study. Dig. Liver Dis. 2013; 45; 377-384.
72. van de Water JM, Cillessen SA, Visser OJ, Verbeek WH, Meijer CJ, Mulder CJ. Enteropathy associated T-cell lymphoma and its precursor lesions. Best Pract. Res. Clin. Gastroenterol. 2010; 24; 43-56.
73. Swerdlow SH, Jaffe ES, Brousset P et al. Cytotoxic T-cell and NK-cell lymphomas: current questions and controversies. Am. J. Surg. Pathol. 2014; 38; e60-e71.
74. Lebwohl B, Granath F, Ekbom A et al. Mucosal healing and risk for lymphoproliferative malignancy in celiac disease: a population-based cohort study. Ann. Intern. Med. 2013; 159; 169-175.
75. Malamut G, Meresse B, Cellier C, Cerf-Bensussan N. Refractory celiac disease: from bench to bedside. Semin. Immunopathol. 2012; 34; 601-613.
76. Isaacson P, Wright DH. Malignant histiocytosis of the intestine. Its relationship to malabsorption and ulcerative jejunitis. Hum. Pathol. 1978; 9; 661-677.
77. Sabattini E, Pizzi M, Tabanelli V et al. CD30 expression in peripheral T-cell lymphomas. Haematologica 2013; 98; e81-e82.
78. Bossard C, Dobay MP, Parrens M et al. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation between protein and mRNA expression. Blood 2014; 124: 2983-2986.
79. Khalaf WF, Caldwell ME, Reddy N. Brentuximab in the treatment of CD30-positive enteropathy-associated T-cell lymphoma. J. Natl. Compr. Canc. Netw. 2013; 11; 137-140; quiz 40.
80. Chan JK, Chan AC, Cheuk W et al. Type II enteropathy-associated T-cell lymphoma: a distinct aggressive lymphoma with frequent gammadelta T-cell receptor expression. Am. J. Surg. Pathol. 2011; 35; 1557-1569.
81. Tan SY, Chuang SS, Tang T et al. Type II EATL (epitheliotropic intestinal T-cell lymphoma): a neoplasm of intra-epithelial T-cells with predominant CD8alphaalpha phenotype. Leukemia 2013; 27; 1688-1696.
82. Tan SY, Ooi AS, Ang MK et al. Nuclear expression of MATK is a novel marker of type II enteropathy-associated T-cell lymphoma. Leukemia 2011; 25; 555-557.
83. Akiyama T, Okino T, Konishi H et al. CD8 +, CD56 + (natural killer-like) T-cell lymphoma involving the small intestine with no evidence of enteropathy: clinicopathology and molecular study of five Japanese patients. Pathol. Int. 2008; 58; 626-634.
84. Au WY, Weisenburger DD, Intragumtornchai T et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 2009; 113; 3931-3937.
85. Chuang SS, Chang ST, Chuang WY et al. NK-cell lineage predicts poor survival in primary intestinal NK-cell and T-cell lymphomas. Am. J. Surg. Pathol. 2009; 33; 1230-1240.
86. Pongpruttipan T, Sukpanichnant S, Assanasen T et al. Extranodal NK/T-cell lymphoma, nasal type, includes cases of natural killer cell and alphabeta, gammadelta, and alphabeta/gammadelta T-cell origin: a comprehensive clinicopathologic and phenotypic study. Am. J. Surg. Pathol. 2012; 36; 481-499.
87. Kim JH, Lee JH, Lee J et al. Primary NK-/T-cell lymphoma of the gastrointestinal tract: clinical characteristics and endoscopic findings. Endoscopy 2007; 39; 156-160.
88. Ryan JL, Shen YJ, Morgan DR et al. Epstein-Barr virus infection is common in inflamed gastrointestinal mucosa. Dig. Dis. Sci. 2012; 57; 1887-1898.
89. Huang Y, de Leval LL, Gaulard P. Molecular underpinning of extranodal NK/T-cell lymphoma. Best Pract. Res. Clin. Haematol. 2013; 26; 57-74.
90. Huang Y, de Reynies A, de Leval L et al. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood 2010; 115; 1226-1237.
91. Bouchekioua A, Scourzic L, de Wever WO et al. JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. Leukemia 2014; 28; 338-348.
92. Perry AM, Warnke RA, Hu Q et al. Indolent T-cell lymphoproliferative disease of the gastrointestinal tract. Blood 2013; 122; 3599-3606.
93. Leventaki V, Manning JT Jr, Luthra R et al. Indolent peripheral T-cell lymphoma involving the gastrointestinal tract. Hum. Pathol. 2014; 45; 421-426.
94. Malamut G, Meresse B, Kaltenbach S et al. Small intestinal CD4 + T-cell lymphoma is a heterogenous entity with common pathology features. Clin. Gastroenterol. Hepatol. 2014; 12; 599-608 e1.
95. Mansoor A, Pittaluga S, Beck PL, Wilson WH, Ferry JA, Jaffe ES. NK-cell enteropathy: a benign NK-cell lymphoproliferative disease mimicking intestinal lymphoma: clinicopathologic features and follow-up in a unique case series. Blood 2011; 117; 1447-1452.
96. Takeuchi K, Yokoyama M, Ishizawa S et al. Lymphomatoid gastropathy: a distinct clinicopathologic entity of self-limited pseudomalignant NK-cell proliferation. Blood 2010; 116; 5631-5637.
97. Koh J, Go H, Lee WA, Jeon YK. Benign Indolent CD56-Positive NK-Cell Lymphoproliferative Lesion Involving Gastrointestinal Tract in an Adolescent. Korean J. Pathol. 2014; 48; 73-76.
98. Kinch A, Baecklund E, Backlin C et al. A population-based study of 135 lymphomas after solid organ transplantation: the role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival. Acta Oncol. 2014; 53; 669-679.
99. Swerdlow SH. T-cell and NK-cell posttransplantation lymphoproliferative disorders. Am. J. Clin. Pathol. 2007; 127; 887-895.
100. Cesarman E. Gammaherpesviruses and lymphoproliferative disorders. Annu. Rev. Pathol. 2014; 9; 349-372.
101. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370; 59-67.
102. Bai M, Katsanos KH, Economou M et al. Rectal Epstein-Barr virus-positive Hodgkin's lymphoma in a patient with Crohn's disease: case report and review of the literature. Scand. J. Gastroenterol. 2006; 41; 866-869.
103. de Leval L, Gisselbrecht C, Gaulard P. Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. Br. J. Haematol. 2010; 148; 673-689.
104. Dojcinov SD, Venkataraman G, Raffeld M, Pittaluga S, Jaffe ES. EBV positive mucocutaneous ulcer-a study of 26 cases associated with various sources of immunosuppression. Am. J. Surg. Pathol. 2010; 34; 405-417.
105. Hart M, Thakral B, Yohe S et al. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder. Am. J. Surg. Pathol. 2014; 38; 1522-1529.